Navigation Links
QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer
Date:8/16/2011

, the QIAGEN assay can be useful in identifying patients most appropriate for EGFR-inhibitor therapies. QIAGEN recently submitted the application for Premarket Approval (PMA) for KRAS companion diagnostics to the FDA for use with two other, separate drugs targeting metastatic colorectal cancers. The Pfizer drug companion diagnostic test is being specifically developed for use in lung cancer tissue. It uses the same core assay component as the therascreen KRAS RGQ kit for colorectal cancers but varies in the workflow to allow for lung tissue-specific sample technology in a fully automated workflow.

QIAGEN and Pfizer will engage in collaborative efforts to develop the KRAS companion diagnostic for use with dacomitinib (PF-00299804). The global partnership covers clinical trials and submissions for a PMA application in the United States and the CE mark in Europe, as well as applicable regulatory approvals in other regions.

"We are pleased to collaborate with Pfizer seeking to advance personalized healthcare with a new potential tool in the fight against non-small cell lung cancer, a major killer around the world," commented Dr. Stephen Little, Vice President Personalized Healthcare at QIAGEN. "This partnership unites QIAGEN's capabilities in companion diagnostics with Pfizer's scientific excellence and global presence to develop an innovative diagnostic-therapeutic combination with the potential to improve the standard of care for NSCLC patients."

Lung cancer is the most common cancer globally in incidence and mortality. About 1.1 million new cases are reported each year in males, with 0.95 million deaths, and 0.51 million new cases per year are reported in females, with 0.43 million deaths. Worldwide, approximately 85% of all lung cancers are classified as non-small cell lung cancer, with a five-year survival rate of only about 15%.

"QIAGEN has invested deeply in Personalized Healt
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
2. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9
3. QIAGEN Acquires ESE GmbH
4. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
5. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
6. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
8. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
9. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
10. Pfizer Receives Complete Response Letter from FDA for REMOXY®
11. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 ... Market by Tumor (Breast, Lung, Prostate) Type (Protein & ... (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast ... is expected to reach around 17,689.0 Million USD by ... period of 2015 to 2020. Browse ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... DIEGO, Nov. 24 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ... Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009 ... is being held at The New York Palace Hotel. ... will provide an overview of Anadys and its clinical development ...
... , POTOMAC, Md., Nov. 24 In ... has added Philadelphia jurors to her Thanksgiving gratitude list. ... I am so thankful to them," she said of Monday,s ... , Wisneski is among 12,000 women nationwide who have sued ...
Cached Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Maryland Woman Thankful for Wyeth Verdicts 2
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... Rio ... O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information Services. ... eager to help the college expand its reach and impact through innovative technologies and ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... , ... Brands like Toppik , Eau Thermale Avene and Bliss are ... threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, ... for customers regardless of the item’s selling price.” , With competitive pricing in the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... center management, Decatur County Memorial Hospital recently transitioned management companies to partner with ... Center Management for their outpatient wound center. , Transitioning wound care management ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... of Experimental Medicine -, - Findings Underscore Versatility ... Antagonists as Possible ... TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ) today announced ... Hopkins University (JHU) for intellectual property,related to the novel ...
... Blue Cross and Blue Shield of,Florida ... been appointed Market,President - West Florida, effective ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ), ... has served in a number of leadership ...
... May 1 Cadient Group, the,premier strategic interactive ... has appointed Barbara Dowling as Senior Vice,President, Customer ... on both the client and agency side, Barb ... to address business critical,issues. In this role, Dowling ...
... 1 Nu Skin Enterprises, Inc.,(NYSE: NUS ... a 9,percent improvement over the prior-year period. Earnings ... 31 percent increase compared to the same,quarter of ... 6 percent,by foreign currency fluctuations. Quarterly earnings per ...
... Calif., May 1 Cardiogenesis,Corporation (Pink Sheets: CGCP), ... first quarter ended March 31, 2008 prior to ... also said that President Richard P.,Lanigan and Senior ... will host an investor conference call that day ...
... Performs with Peerless Safety and Proven Efficacy in all Four ... Chambers of the Heart, Stereotaxis to Introduce ... ... May 1 Stereotaxis, Inc. (Nasdaq:,STXS), announced today that approximately 15,000 procedures have been,performed ...
Cached Medicine News:Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 2Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 3Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 4Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 2Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 3Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 4Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 5Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 6Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 7Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 8Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 9Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 10Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 2Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 3Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 4
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) IgA isotype in human serum....
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
Medicine Products: